Astrazeneca (AZN) Gross Margin (2009 - 2026)
Astrazeneca (AZN) posted quarterly Gross Margin of 83.6% for Q2 2026, up 71.0% year-over-year from 48.89% in Q2 2025, and down 99.49% quarter-over-quarter from 16376.62% in Q1 2026.
Astrazeneca (AZN) Gross Margin (2009 - 2026) Analysis & Trends
Astrazeneca's Gross Margin history runs 18 years deep, the most recent figure standing at 83.6% for Q2 2026.
- In Q2 2026, Gross Margin rose 71.0% year-over-year to 83.6%; the TTM figure through Jun 2026 stood at 324.63% (up 2615.0% YoY), while the FY2025 annual figure was 81.9%, up 77.0% from the prior year.
- Gross Margin for Q2 2026 stood at 83.6%, down from 16376.62% in the prior quarter.
- The five-year high for Gross Margin was 268875.0% in Q2 2024, with the low at 82.89% in Q2 2025.
- The 5-year median for Gross Margin is 12510.71% (2025), against an average of 55045.67%.
- The sharpest annual moves came in 2024 and 2025: Gross Margin soared 26397552 bps in 2024, then tumbled 26879211 bps in 2025.
- Astrazeneca's Gross Margin stood at 5257.59% in 2022, then surged by 67 bps to 8778.23% in 2023, then slumped by 83 bps to 1492.76% in 2024, then soared by 13728 bps to 206416.67% in 2025, then slumped by 100 bps to 83.6% in 2026.
- Business Quant data shows AZN's Gross Margin at 83.6% in Q2 2026, 16376.62% in Q1 2026, and 206416.67% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 78.02% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 83.60% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 72.04% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 79.76% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 72.78% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 73.05% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83.60% |
| Mar 31, 2026 | 16,376.62% |
| Dec 31, 2025 | 206,416.67% |
| Sep 30, 2025 | 112,636.36% |
| Jun 30, 2025 | 82.89% |
| Mar 31, 2025 | 15,333.78% |
| Dec 31, 2024 | 1,492.76% |
| Sep 30, 2024 | 17,769.49% |
| Jun 30, 2024 | 268,875.00% |
| Mar 31, 2024 | 23,246.67% |
| Dec 31, 2023 | 8,778.23% |
| Sep 30, 2023 | 9,687.63% |
| Jun 30, 2023 | 4,899.48% |
| Mar 31, 2023 | 33,237.04% |
| Dec 31, 2022 | 5,257.59% |
| Sep 30, 2022 | 4,494.38% |
| Jun 30, 2022 | 259,100.00% |
| Mar 31, 2022 | 3,053.88% |
| Dec 31, 2021 | 1,439.77% |
| Sep 30, 2021 | 4,887.20% |